The 18-Month MDR-TB Regimen Has a Successor - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

The 18-Month MDR-TB Regimen Has a Successor

Six months, all-oral, better tolerated—and the infrastructure to make it work.

  • By

  • Kerri Miller

  • April 16, 2026

  • 3 min

Share

  • 1

    Pretomanid prescribing in NHS England increased fivefold from early 2024 to 2025, reflecting successful implementation of shorter MDR-TB regimens.

  • 2

    Evidence supports 6 to 9 month bedaquiline-based regimens, showing favorable outcomes of 84% to 93% across various trial populations.

  • 3

    Implementation in the UK involved expert oversight, a funded access pathway, and drug-specific monitoring to ensure safe prescribing.

  • 4

    Shorter regimens reduce pill burden and adverse events, improving adherence and freeing clinical capacity for healthcare providers.

  • 5

    The UK model illustrates necessary system design for safe and equitable MDR-TB treatment, despite limitations in drug safety monitoring.

Original Source(s)

The 18-Month MDR-TB Regimen Has a Successor

  • by Kerri Miller

  • April 16, 2026

Related Content

Hemodynamic Instability in Intubation May Be Predictable

Narrative review describes how physiologic stressors accumulate from induction through postintubation care and may contribute to cardiovascular deterioration during airway management.

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

Assessment of Potential Drug–Drug Interactions and Associated Factors Among Pulmonary Inpatients in a Tertiary Care Hospital: A Cross-Sectional Study